4 results
Primary: Safety and tolerability. Secondary: Effectiveness, quality of life, healthcare resource utilisation, work productivity.
Primary Objective:To induce clinical response (CDAI decrease from baseline * 100 points) and/or remission(CDAI <150) following 12 weeks of treatment with one of two active doses ofGSK1605786A for qualification of subjects for enrolment into a…
Main objective: To determine the efficacy of pemigatinib in participants with recurrent GBM with an activating FGFR1-3 mutation or fusion/rearrangement. Secondary objectives: 1. To determine the efficacy of pemigatinib in participants with recurrent…
To assess whether ADRB2 genotype-guided asthma treatment in children with persistend athma symptoms despite ICS treatment leads to better asthma control compared to non-genotype-guided asthma treatment.